Major ALKPositive Huge B Cell Lymphoma involving Pancreas

breast cancer, and it prolongs the survival of patients, with tolerable adverse reactions, which is worthy of further clinical application.
Bevacizumab combined with docetaxel has more excellent efficacy than docetaxel alone in the treatment of HER-2-negative recurrent metastatic breast cancer, and it prolongs the survival of patients, with tolerable adverse reactions, which is worthy of further clinical application.
Long non-coding RNAs (LncRNAs) are thought as tumorigenic factors in cancer progression. We investigated the clinical significance of arylsulfatase D (ARSD) and ARSD antisense in breast cancer patients.
Eighty breast cancer tumors were obtained from the Tumor Bank of Cancer Institute, Imam Khomeini Hospital. The expression level of ARSD and ARSD-AS1 were examined in breast tumors in comparison to the margin of normal tissues using quantitative real-time PCR. Demographic information and the clinicopathologic characteristics including tumor grade, presence of cell receptors, lymph node and vascular invasion were also evaluated. Bioinformatics databases were used for identification of ARSD and ARSD-AS1 molecular targets and their association with cancer.
Significant up-regulation of ARSD was observed in tumor tissues in comparison with its antisense (p<0.05). Both ARSD and ARSD-AS1 expression in tumor specimens were notably lower than those in adjacent normal tissue. High expression of ARSD was associated to lower tumor grade (p<0.05). Bioinformatics results revealed the interaction of ARSD with STS and SUMF1 proteins was attributed to the inhibiting of sulfates activity. Also, ARSD co-expressed genes were associated with oncogenic transcription factors, MAF and GATA. TP53 transcription factor site was identified as a target of ARSD-AS1 mRNA. The interaction of this antisense with microRNA (miR-618) could explain its participation in tumor cell proliferation.
Low expression of ARSD was associated with higher tumor grade. The evidence from this study enhance our understanding of ARSD and ARSD-AS1 function in cancer gene therapy. Accordingly, they could be introduced as great potential targets for breast cancer treatment.
Low expression of ARSD was associated with higher tumor grade. The evidence from this study enhance our understanding of ARSD and ARSD-AS1 function in cancer gene therapy. Accordingly, they could be introduced as great potential targets for breast cancer treatment.
To analyze the activity and safety of denosumab (DNS) 120 mg every 3 months over 2 years of standard treatment (120 mg SC every 4 weeks) of patients with breast cancer bone metastases in real life.
We prospectively analyzed the activity and safety of denosumab 120 mg every 3 months and 120 mg every 4 weeks in the treatment of 22 patients with breast cancer bone metastases over 2 years of standard treatment. All patients received specific concomitant antineoplastic treatment, chemotherapy or endocrine therapy and/or target therapy. Oral daily calcium (≥500 mg) and vitamin D (≥1000 U) supplement was recommended.
Of the 22 patients treated with denosumab, 4 (18.1%) had at least 1 skeletal related event (SRE); 3 (13.6%) had 1 SRE and 1 patient (4.5%) had 2 SRE, all 10% treated with radiotherapy. Overall, no denosumab-related G3 adverse events occurred; in particular, no cases of osteonecrosis of the jaw have been recorded. The decrease in serum calcium levels was mild (G1, 2 patients, 9%), and recovered in a short time (within 2 weeks) with an increase in the oral support of calcium and vitamin D.
Denosumab confirms a good activity profile in terms of delaying and preventing SREs in breast cancer patients and a good safety profile. It represents an optimal treatment resource which doesn't necessitate renal function monitoring and has the convenience of a subcutaneous administration.
Denosumab confirms a good activity profile in terms of delaying and preventing SREs in breast cancer patients and a good safety profile. It represents an optimal treatment resource which doesn't necessitate renal function monitoring and has the convenience of a subcutaneous administration.
To explore the inhibition of proliferation and invasion of breast cancer cells by LncRNA SNHG7 via regulating the expression of miR-15a and its mechanism.
The expression of SNHG7 in breast cancer and adjacent tissues and different breast cancer cells was measured by qRT-PCR and the relationship between SNHG7 and clinicopathological parameters of breast cancer patients was analyzed. Selleck LY3537982 The interaction of SNHG7 with miR-15a was explored by dual-luciferase reporter assay. The change in the proliferation of breast cancer cells after silencing SNHG7 was examined by cell proliferation assay. The change in the invasion of breast cancer cells after silencing SNHG7 was examined by Transwell invasion assay. Subcutaneous tumor formation in nude mice was detected to record the tumor size and volume of tumor cells.
Compared with adjacent normal tissues, the expression of SNHG7 was significantly increased in breast cancer tissues; the expression of SNHG7 was the highest in breast cancer cells MCF7 and T47D; the expressi miR-15a activity.
To explore the clinical application value of color Doppler ultrasound combined with computed tomography (CT) in the diagnosis of axillary lymph node metastasis (ALNM) in breast cancer.
From January 2016 to June 2018, 189 breast cancer patients who underwent radical mastectomy in our hospital were included and retrospectively analyzed. All patients had preoperative color Doppler ultrasound and CT examination of mammary gland and axillary lymph nodes, with pathological diagnosis as the gold standard. Eighty-eight cases were divided into axillary lymph node metastasis group (metastatic group) and 101 cases formed the non-axillary lymph node metastasis group (non-metastatic group). The ultrasound and CT imaging of axillary lymph nodes were analyzed to evaluate the value of color Doppler ultrasound combined with CT in the assessment of axillary lymph node metastasis in breast cancer.
Ultrasonographic metastatic lymph nodes showed unclear borders and eccentric thickening of the cortex. The enhancement scan showed obvious heterogeneous enhancement and disappearance of lymphatic structure.